Melanoma News and Research

Latest Melanoma News and Research

Jennerex initiates JX-594 plus irinotecan Phase 1/2 trial in metastatic colorectal cancer

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that the first patient has been treated in a Phase 1/2 clinical trial of JX-594 in patients with metastatic colorectal cancer who have become refractory to chemotherapy and are either refractory to or ineligible for cetuximab.

20 Mar 2012

Mayo Clinic researchers train mouse immune systems to eradicate skin cancer from within

Mayo Clinic researchers have trained mouse immune systems to eradicate skin cancer from within, using a genetic combination of human DNA from melanoma cells and a cousin of the rabies virus. The strategy, called cancer immunotherapy, uses a genetically engineered version of the vesicular stomatitis virus to deliver a broad spectrum of genes derived from melanoma cancer cells directly into tumors.

20 Mar 2012

IOB, Delcath to launch CHEMOSAT system for Spanish cancer patients

Delcath Systems, Inc. announced today that the Company has entered into an initial launch and training agreement for the Delcath Hepatic CHEMOSAT Delivery system with the Instituto Oncologico Baselga (IOB), Grupo Quiron—a private hospital located in Barcelona, Spain.

19 Mar 2012

Top-line data from Provectus' PH-10 Phase 2 trial on plaque psoriasis

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced top-line data for the company's randomized controlled trial (RCT) of PH-10 for mild-to-moderate plaque psoriasis.

19 Mar 2012

Oral BRAF inhibitor can extend survival to 16 months for patients with MM

An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center in Tampa, Fla., have found that the oral BRAF inhibitor vemurafenib (PLX4032) when tested in a phase II clinical trial offered a high rate of response in patients with previously treated metastatic melanoma and who had the BRAF mutation.

17 Mar 2012

Life-extending pill for advanced melanoma now available in UK

A life-extending pill for advanced melanoma that The Institute of Cancer Research (ICR) and The Royal Marsden Hospital helped develop is now available in the UK.

14 Mar 2012

Cancer rates to fall among men but slightly rise among women by 2020: Report

The report says that due to the growing and ageing population the actual number of new cases will rise by almost 40 per cent on 2007 levels. But when that's converted to the number of cases per 100,000 people the results are surprising. Cancer rates in men will fall from 595 to 568 cases per 100,000 by 2020. That equates to about 85,000 cases. When it comes to women the rate is projected to rise from 394 to 408 cases per 100,000. That's equivalent to 65,000 new cases in 2020.

11 Mar 2012

Combining radiation therapy with ipilimumab shows promise against melanoma

Research published today in the New England Journal of Medicine by scientists at the Ludwig Institute for Cancer Research (LICR) and Memorial Sloan-Kettering Cancer Center (MSKCC) showed that combining targeted radiation therapy with immunotherapy (ipilimumab), fostered a strong immune response and a favorable clinical outcome in a patient with melanoma, the most dangerous form of skin cancer.

8 Mar 2012

Illumina launches new highly multiplexed cancer panel

Illumina today introduced the TruSeq Amplicon - Cancer Panel, a highly multiplexed panel that will allow researchers to accurately sequence hundreds of the most relevant cancer loci, even in difficult samples such as formalin-fixed, paraffin embedded (FFPE) tumor samples.

From Illumina, Inc. 7 Mar 2012

Study identifies mechanism that explains how cancer cells spread to the lymph nodes

Metastasis is responsible for 90% of deaths in patients with cancer. Understanding the mechanisms responsible for this process is one of the top goals of cancer research. The metastatic process involves a series of steps chained where the primary tumour invades surrounding tissues and ends spreading throughout the body. Ones of the first tissues undergoing metastasis are the lymph nodes surrounding the tumour.

7 Mar 2012

Researchers reveal how melanoma develops resistance to Zelboraf

Cancer is tough to kill and has many ways of evading the drugs used by oncologists to try and eliminate it. Now, researchers at UCLA's Jonsson Comprehensive Cancer Center have uncovered how an advanced form of melanoma gets around an inhibitor, Zelboraf, which targets the mutated BRAF gene.

7 Mar 2012

IDS, AADA disappointed in postponement of vote by Idaho on indoor tanning bed legislation

The Idaho Dermatology Society (IDS) and the American Academy of Dermatology Association (AADA) are disappointed in the postponement of the vote by the Idaho House of Representatives on House Bill 486, which would ban the use of indoor tanning beds by minors under the age of 18.

5 Mar 2012

Vitamin A daily dose may help prevent skin cancer: Study

A study has shown that a daily vitamin pill could help prevent skin cancer - particularly among women. Scientists say taking food supplements containing vitamin A can make people less likely to develop melanoma, the deadliest form of the disease.

4 Mar 2012

Northern Ireland has higher survival rates for pancreatic cancer, leukaemia

The first audit of leukaemia treatment and survival in Northern Ireland by the Cancer Registry (NICR) at Queen's University Belfast has shown that survival rates for the disease here are at the highest levels since data collection began in 1993.

2 Mar 2012

New HS44 molecule inhibits lung metastasis

One type of white blood cell, the Natural Killer T Cells, fights against infections and tumours by freeing cytokine proteins which activate the body's immune response and destroy infected or malignant cells. To do so they must receive an activation signal. Specific receptors located on their surface act as switches: they activate the lymphocyte in presence of an antigen, a molecule which triggers alarm signals.

2 Mar 2012

p14 ARF protein also regulates tumor-induced angiogenesis

Researchers at Winship Cancer Institute of Emory University have identified a new function for a gene that normally prevents the development of cancer.

2 Mar 2012

Metastatic melanoma patients with specific genetic mutation benefit from vemurafenib

A report published this week in the New England Journal of Medicine shows that the 50 percent of metastatic melanoma patients with a specific genetic mutation benefit from the drug Vemurafenib - increasing median survival from about 6 months to 15.9 months. In patients who responded, the drug stopped cancer progression for a median 6.7 months.

1 Mar 2012

Non-invasive hyperspectral imaging system for skin cancer screening relies on Andor technology

Malignant melanoma (MM), the most dangerous type of skin cancer, is caused mainly by intense episodes of UV exposure and originates in the pigment-producing melanocytes in the basal layer of the epidermis. Early detection and complete excision of the primary lesions is crucial for reducing melanoma-related deaths but current diagnostic practice is highly subjective. This leads to unnecessary surgical procedures, which are highly-invasive and expensive.

1 Mar 2012

XL888 inhibitor can prevent vemurafenib resistance in melanoma patients

Researchers at Moffitt Cancer Center in Tampa, Fla., and colleagues in California have found that the XL888 inhibitor can prevent resistance to the chemotherapy drug vemurafenib, commonly used for treating patients with melanoma.

29 Feb 2012

First patients in Germany treated with Delcath Hepatic CHEMOSAT Delivery System

Delcath Systems, Inc., announced today that the first patients in Germany have been treated with the Delcath Hepatic CHEMOSAT Delivery System at the Johann Wolfgang Goethe University Hospital, a premier European cancer treatment and research center located in Frankfurt. The cases were treated as part of the initial launch and training agreement the Company announced with the hospital in December 2011.

27 Feb 2012